01/22/2026
✨ A meaningful and exciting milestone – our collaborative NephroNet study received official approval in the United States in January 2026!
We are pleased to share that our clinical research, conducted together with NephroNet focused on evaluating electro-hydraulic acoustic therapy to enhance renal blood flow and glomerular filtration in patients with Stage III diabetic nephropathy, received IRB approval in the U.S. in January 2026.
The approval granted by Advarra IRB, allows us to proceed to the next phase of the study following a thorough review of the protocol, informed consent forms, and required modifications. This represents an important step forward for our joint teams and for the patients who may one day benefit from this innovative approach.
We’re proud to continue advancing a novel therapy with the potential to significantly improve outcomes for individuals living with diabetic kidney disease.
A heartfelt thank you to our research team, our partners at NephroNet, collaborators, and everyone who contributed to reaching this milestone.
Now, we move forward — with commitment, optimism, and purpose.